SJP1804 / AptaBio, Samjin Pharma - LARVOL DELTA

[VIRTUAL] The efficacy evaluation study of the clinical eye drop formulation of the NOX inhibitor, SJP1804 and the design of a phase 1 clinical trial for the treatment of wet AMD. (ARVO 2021) - "Taken together, the results showed that excellent efficacy of the clinical eye drop formulation of SJP1804 (0.25% API) in CNV. Considering the fact that the intraocular half-life of various drugs in human is about 2.5 times longer than that in rabbit, it is supposed that 1~3 times/day administration of SJP1804 eye drop is sufficient to exert clinical efficacy. Based on the results, we further designed phase 1 clinical trial of SJP1804 (0.25% API) eye drop in health Korean and Caucasian male subjects for investigating PK, safety and local tolerability."

Clinical • P1 data • Age-related Macular Degeneration • Ophthalmology • Wet Age-related Macular Degeneration